These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29719371)

  • 81. A PROCESS OF PRIORITIZING TOPICS FOR HEALTH TECHNOLOGY ASSESSMENT IN KAZAKHSTAN.
    Kosherbayeva L; Hailey D; Kurakbaev K; Tabarov A; Kumar A; Gutzskaya G; Stepkina E
    Int J Technol Assess Health Care; 2016 Jan; 32(3):147-51. PubMed ID: 27502426
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Priority setting for health technology assessment at CADTH.
    Husereau D; Boucher M; Noorani H
    Int J Technol Assess Health Care; 2010 Jul; 26(3):341-7. PubMed ID: 20584365
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Weighing the evidence: trends in managed care formulary decision making.
    de Lissovoy G
    J Clin Psychiatry; 2003; 64 Suppl 17():29-32. PubMed ID: 14680425
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Development and implementation of a comprehensive, criteria-based drug-use review program.
    Todd MW; Keith TD; Foster MT
    Am J Hosp Pharm; 1987 Mar; 44(3):529-35. PubMed ID: 3471089
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Evaluating a restrictive formulary system by assessing nonformulary-drug requests.
    Green JA; Chawla AK; Fong PA
    Am J Hosp Pharm; 1985 Jul; 42(7):1537-41. PubMed ID: 4025350
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion.
    Janknegt R; Steenhoek A
    Drugs; 1997 Apr; 53(4):550-62. PubMed ID: 9098659
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The formulary decision-making process in a health maintenance organisation setting.
    Shepherd MD; Salzman RD
    Pharmacoeconomics; 1994 Jan; 5(1):29-38. PubMed ID: 10146864
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Factors that influence prescribing decisions.
    Schumock GT; Walton SM; Park HY; Nutescu EA; Blackburn JC; Finley JM; Lewis RK
    Ann Pharmacother; 2004 Apr; 38(4):557-62. PubMed ID: 14966259
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Acceptance of a pharmacy-based, physician-edited hospital pharmacy and therapeutics committee newsletter.
    Ritchie DJ; Manchester RF; Rich MW; Rockwell MM; Stein PM
    Ann Pharmacother; 1992; 26(7-8):886-9. PubMed ID: 1504393
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Use of multiattribute utility theory for formulary management in a health system.
    Chung S; Kim S; Kim J; Sohn K
    Am J Health Syst Pharm; 2010 Jan; 67(2):128-35. PubMed ID: 20065267
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Incorporation of a mock pharmacy and therapeutics committee as an entrustable professional activity supporting task.
    Borja-Hart NL; Rowe AS; Gatwood J; Wheeler J
    Curr Pharm Teach Learn; 2021 Jul; 13(7):784-788. PubMed ID: 34074508
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacy formularies in integrated health systems.
    Osborne JA
    J Healthc Resour Manag; 1997; 15(1):18-20. PubMed ID: 10164678
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Improving pharmacy and therapeutics committee operations.
    Cohen MR; Klapp D; Miller KB; Shaffer VL; Slotfeldt M; Miller DE
    Am J Hosp Pharm; 1984 Sep; 41(9):1767-77. PubMed ID: 6496511
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Formulary decisions: then and now.
    Boucher BA
    Pharmacotherapy; 2010 Jun; 30(6 Pt 2):35S-41S. PubMed ID: 20500042
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Formulary evaluation using a class review approach: experience and results from an academic medical center.
    Persson EL; Miller KS; Nieman JA; Sgourakis AP; Akkerman SR
    P T; 2013 Apr; 38(4):213-6. PubMed ID: 23785226
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Economic Outcomes Associated with a Pharmacist-Adjudicated Formulary Consult Service in a Veterans Affairs Medical Center.
    Britt RB; Hashem MG; Bryan WE; Kothapalli R; Brown JN
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1051-61. PubMed ID: 27579827
    [TBL] [Abstract][Full Text] [Related]  

  • 99. An innovative tool to prioritize the assessment of investigational COVID-19 therapeutics: A pilot project.
    Béïque L; Clarke S; Azad M; Sarwar E; Gale-Rowe M; Sabourin S; Marinsky C; Arthur J
    Can Commun Dis Rep; 2024 Oct; 50(10):357-364. PubMed ID: 39380802
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Lomitapide: A Medication Use Evaluation and a Formulary Perspective.
    Esba LCA; Alharbi H
    Glob J Qual Saf Healthc; 2024 May; 7(2):59-62. PubMed ID: 38725887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.